Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Net Margin (2024 - 2025)

Monte Rosa Therapeutics' Net Margin history spans 2 years, with the latest figure at 1658.94% for Q4 2025.

  • For Q4 2025, Net Margin fell 176258.0% year-over-year to 1658.94%; the TTM value through Dec 2025 reached 31.23%, down 43.0%, while the annual FY2025 figure was 31.23%, 45.0% down from the prior year.
  • Net Margin reached 1658.94% in Q4 2025 per GLUE's latest filing, down from 212.1% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 103.65% in Q4 2024 to a low of 3006.11% in Q1 2024.